Compare GGT & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GGT | SPRO |
|---|---|---|
| Founded | 1994 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.4M | 156.3M |
| IPO Year | N/A | 2017 |
| Metric | GGT | SPRO |
|---|---|---|
| Price | $4.07 | $1.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 358.4K | ★ 1.5M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 15.56% | N/A |
| EPS Growth | N/A | ★ 111.81 |
| EPS | ★ 0.83 | N/A |
| Revenue | N/A | ★ $66,802,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $300.00 |
| P/E Ratio | $4.92 | ★ N/A |
| Revenue Growth | N/A | ★ 39.24 |
| 52 Week Low | $3.87 | $1.10 |
| 52 Week High | $4.39 | $3.08 |
| Indicator | GGT | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 37.43 | 18.94 |
| Support Level | $4.00 | N/A |
| Resistance Level | $4.10 | $2.44 |
| Average True Range (ATR) | 0.04 | 0.16 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 16.96 | 6.19 |
Gabelli Multimedia Trust Inc is a non-diversified closed-end management investment company. Its investment objective is the long-term growth of capital with income as a secondary objective. The fund invests majority of its assets, under normal market conditions, in common stock and other securities, including convertible securities, preferred stock, options, and warrants of companies in the telecommunications, media, publishing, and entertainment industries.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.